LAPATINIB DITOSYLATE vs LASMIDITAN: Which Drug Is Safer?
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
LAPATINIB DITOSYLATE vs LASMIDITAN: Safety Overview
| Metric | LAPATINIB DITOSYLATE | LASMIDITAN |
|---|---|---|
| Total FAERS Reports | 3,948 | 927 |
| Deaths Reported | 921 | 12 |
| Death Rate | 23.3% | 1.3% |
| Hospitalizations | 752 | 23 |
| Average Patient Age | 57.3 yrs | 47.0 yrs |
| % Female Patients | 95.0% | 85.4% |
| FDA Approval Date | Aug 16, 2024 | Dec 18, 2020 |
| Manufacturer | AvKARE | Eli Lilly and Company |
| Route | ORAL | ORAL |
| Marketing Status | Prescription | Prescription |